| Author |
Message |
Yahoo News Bot
Joined: 01 Feb 2005
Posts: 33404
|
 Posted:
Thu Feb 03, 2005 10:30 am |
  |
Reuters - Gilead Sciences on Thursday said
preliminary data from a 48-week trial show that two of its two
drugs, Viread and Emtriva, were better able to control levels
of HIV than Combivir, a popular treatment sold by
GlaxoSmithKline Plc.
Read more... |
|
|
|
|
|
|
| |
